Compare AANJANEYA LIFECARE with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. DATSONS LABS vs TORRENT PHARMA - Comparison Results

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. DATSONS LABS TORRENT PHARMA DR. DATSONS LABS/
TORRENT PHARMA
 
P/E (TTM) x -10.9 44.0 - View Chart
P/BV x 0.2 10.5 1.5% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 DR. DATSONS LABS   TORRENT PHARMA
EQUITY SHARE DATA
    DR. DATSONS LABS
Mar-14
TORRENT PHARMA
Mar-19
DR. DATSONS LABS/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs1261,964 6.4%   
Low Rs311,245 2.5%   
Sales per share (Unadj.) Rs133.0453.4 29.3%  
Earnings per share (Unadj.) Rs0.225.8 0.6%  
Cash flow per share (Unadj.) Rs6.662.3 10.6%  
Dividends per share (Unadj.) Rs017.00 0.0%  
Dividend yield (eoy) %01.1 0.0%  
Book value per share (Unadj.) Rs128.8279.2 46.1%  
Shares outstanding (eoy) m31.66169.22 18.7%   
Bonus/Rights/Conversions FCCB--  
Price / Sales ratio x0.63.5 16.6%   
Avg P/E ratio x516.162.2 829.4%  
P/CF ratio (eoy) x11.825.8 46.0%  
Price / Book Value ratio x0.65.7 10.6%  
Dividend payout %065.9 0.0%   
Avg Mkt Cap Rs m2,477271,513 0.9%   
No. of employees `000NA13.6 0.0%   
Total wages/salary Rs m5614,038 0.4%   
Avg. sales/employee Rs ThNM5,642.6-  
Avg. wages/employee Rs ThNM1,032.4-  
Avg. net profit/employee Rs ThNM320.9-  
INCOME DATA
Net Sales Rs m4,21176,728 5.5%  
Other income Rs m79571 13.8%   
Total revenues Rs m4,28977,299 5.5%   
Gross profit Rs m56919,831 2.9%  
Depreciation Rs m2046,177 3.3%   
Interest Rs m4305,038 8.5%   
Profit before tax Rs m139,187 0.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m0-3,570 0.0%   
Tax Rs m61,254 0.5%   
Profit after tax Rs m54,363 0.1%  
Gross profit margin %13.525.8 52.3%  
Effective tax rate %48.013.6 352.0%   
Net profit margin %0.15.7 2.0%  
BALANCE SHEET DATA
Current assets Rs m6,85250,375 13.6%   
Current liabilities Rs m6,71151,653 13.0%   
Net working cap to sales %3.3-1.7 -201.1%  
Current ratio x1.01.0 104.7%  
Inventory Days Days16192 174.7%  
Debtors Days Days31868 466.3%  
Net fixed assets Rs m3,67383,648 4.4%   
Share capital Rs m317846 37.4%   
"Free" reserves Rs m3,76146,397 8.1%   
Net worth Rs m4,07847,244 8.6%   
Long term debt Rs m1,67139,129 4.3%   
Total assets Rs m12,633141,209 8.9%  
Interest coverage x1.02.8 36.5%   
Debt to equity ratio x0.40.8 49.5%  
Sales to assets ratio x0.30.5 61.3%   
Return on assets %3.46.7 51.7%  
Return on equity %0.19.2 1.3%  
Return on capital %7.712.3 62.2%  
Exports to sales %22.90-   
Imports to sales %14.30-   
Exports (fob) Rs m964NA-   
Imports (cif) Rs m602NA-   
Fx inflow Rs m96422,103 4.4%   
Fx outflow Rs m6075,522 11.0%   
Net fx Rs m35716,581 2.2%   
CASH FLOW
From Operations Rs m1,34517,981 7.5%  
From Investments Rs m-2,256-2,413 93.5%  
From Financial Activity Rs m-1,200-13,145 9.1%  
Net Cashflow Rs m-2,1112,380 -88.7%  

Share Holding

Indian Promoters % 4.5 71.5 6.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 7.0 -  
FIIs % 1.4 12.6 10.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 94.1 8.8 1,069.3%  
Shareholders   20,807 26,511 78.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. DATSONS LABS With:   TTK HEALTHCARE  ALEMBIC LTD  WYETH LTD  CADILA HEALTHCARE  SUVEN LIFESCIENCES  

Compare DR. DATSONS LABS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Flat; Power and Telecom Stocks Witness Buying(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 48.6% (Quarterly Result Update)

Jul 31, 2020 | Updated on Jul 31, 2020

For the quarter ended June 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 48.6% YoY). Sales on the other hand came in at Rs 21 bn (up 1.7% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 2.0% (Quarterly Result Update)

Jan 28, 2020 | Updated on Jan 28, 2020

For the quarter ended December 2019, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 2.0% YoY). Sales on the other hand came in at Rs 20 bn (down 4.1% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 36.3% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 36.3% YoY). Sales on the other hand came in at Rs 20 bn (up 5.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 32.5% (Quarterly Result Update)

Jul 25, 2019 | Updated on Jul 25, 2019

For the quarter ended June 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 32.5% YoY). Sales on the other hand came in at Rs 20 bn (up 8.0% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 166.7% (Quarterly Result Update)

May 22, 2019 | Updated on May 22, 2019

For the quarter ended March 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 166.7% YoY). Sales on the other hand came in at Rs 19 bn (up 7.8% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

More Views on News

Most Popular

These 5 Smallcaps Deserve a Place in Your Coffee Can Portfolio(Profit Hunter)

Jul 28, 2020

When it comes to quality stocks, doing less is more.

Before You Buy Your First Electric Vehicle Consider Buying this Stock(Profit Hunter)

Jul 29, 2020

As competition intensifies in the electric vehicle space, only few will create huge wealth over the years.

Large Opportunities Are Coming Our Way

Aug 5, 2020

Kenneth Andrade tells us why stocks will bounce back strongly and what he's bullish on.

How to Buy Gold and Silver(Fast Profits Daily)

Jul 27, 2020

In this video I'll show you how to buy bullion the right way.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

DR. DATSONS LABS SHARE PRICE


May 21, 2015 (Close)

TRACK DR. DATSONS LABS

  • Track your investment in DR. DATSONS LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DR. DATSONS LABS

DR. DATSONS LABS - STERLING BIOTECH COMPARISON

COMPARE DR. DATSONS LABS WITH

MARKET STATS